Company: BSX
Filing Date: 2025-08-01
Form Type: 10-Q
Source: 0000885725-25-000041
Chunk: 40

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-08-01
Form: 10-Q
Item: Part I, Item 1
Chunk 40
---
 operating activitiesDepreciation and amortization661 615 Deferred and prepaid income taxes(49)21 Stock-based compensation expense149 129 Goodwill and other intangible asset impairment charges46 276 Net loss (gain) on investments and notes receivable(191)46 Contingent consideration net expense (benefit)0 18 Inventory step-up amortization118 — Other, net72 8 Increase (decrease) in operating assets and liabilities, excluding purchase accounting:Trade accounts receivable(139)(228)Inventories(44)(219)Other assets(108)(126)Accounts payable, accrued expenses and other liabilities(154)(379)Cash provided by (used for) operating activities1,827 977 Investing activities:  Purchases of property, plant and equipment and internal use software(344)(334)Payments for acquisitions of businesses, net of cash acquired(1,248)(95)Payments for investments and acquisitions of certain technologies(110)(139)Proceeds for settlements of hedge contracts69 — Other, net7 12 Cash provided by (used for) investing activities(1,626)(556)Financing activities:  Payment of contingent consideration previously established in purchase accounting(62)(34)Payments for finance leases(42)(25)Payments on short-term borrowings(1,583)(504)Proceeds from long-term borrowings, net of debt issuance costs1,558 2,145 Cash used to net share settle employee equity awards(123)(80)Proceeds from issuances of common stock pursuant to employee stock compensation and purchase plans147 106 Other, net(1)(15)Cash provided by (used for) financing activities(107)1,593 Effect of foreign exchange rates on cash41 (8)Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents135 2,006 Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period606 1,055 Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period$741 $3,062 

Refer to notes to the unaudited consolidated financial statements. Amounts may not add due to rounding.

7

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

(SUPPLEMENTAL INFORMATION)

Six Months Ended June 30,(